Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M, Ueno Y, Konagai S, Fushiki H, Shimada I, Kondoh Y, Saito R, Mori K, Shindou N, Soga T, Sakagami H, Furutani T, Doihara H, Kudoh M, Kuromitsu S. Mori M, et al. Among authors: mori k. Mol Cancer Ther. 2014 Feb;13(2):329-40. doi: 10.1158/1535-7163.MCT-13-0395. Epub 2014 Jan 13. Mol Cancer Ther. 2014. PMID: 24419060
Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.
Imaizumi T, Shimada I, Satake Y, Yamaki S, Koike T, Nigawara T, Kaneko O, Amano Y, Mori K, Yamanaka Y, Nakayama A, Nishizono Y, Shimazaki M, Nagashima T, Kuramoto K. Imaizumi T, et al. Among authors: mori k. Bioorg Med Chem. 2024 Jan 15;98:117581. doi: 10.1016/j.bmc.2023.117581. Epub 2023 Dec 27. Bioorg Med Chem. 2024. PMID: 38176113
Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
Imaizumi T, Akaiwa M, Abe T, Nigawara T, Koike T, Satake Y, Watanabe K, Kaneko O, Amano Y, Mori K, Yamanaka Y, Nagashima T, Shimazaki M, Kuramoto K. Imaizumi T, et al. Among authors: mori k. Bioorg Med Chem. 2022 Oct 1;71:116949. doi: 10.1016/j.bmc.2022.116949. Epub 2022 Jul 30. Bioorg Med Chem. 2022. PMID: 35926326
Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
Hirayama F, Koshio H, Ishihara T, Hachiya S, Sugasawa K, Koga Y, Seki N, Shiraki R, Shigenaga T, Iwatsuki Y, Moritani Y, Mori K, Kadokura T, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S. Hirayama F, et al. Among authors: mori k. J Med Chem. 2011 Dec 8;54(23):8051-65. doi: 10.1021/jm200868m. Epub 2011 Nov 11. J Med Chem. 2011. PMID: 21995444
7,393 results